At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicenter Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in an F.Hoffmann-la Roche- and/or Genentech- Sponsored Study
In Brief
A Phase 3 clinical trial evaluating Onartuzumab, Bevacizumab, and 1 other intervention for Solid Tumor. Completed, enrolled 12 participants across 10 sites in 8 countries.
Detailed Summary
This extension study will provide continued onartuzumab and/or parent trial (P-trial) designated control treatments to participants with cancer who were previously enrolled in a company-sponsored onartuzumab P-trial and who derived benefit, as assessed by the responsible investigator, from the therapy administered in the P-trial. The study will also collect safety data with regard to administration of continued onartuzumab therapy.
Study Details
Timeline
Interventions
Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).
All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.
All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.